Peptide Tools to Study EBV

About EBV (Epstein-Barr Virus)

Epstein-Barr virus (EBV or HHV-4) belongs to the family of Herpesviridae and is known as the cause of infectious mononucleosis. Being able to establish a long-term, latent infection in human B cells, it is prevalent in the adult population (worldwide 90%).

EBV is associated with a range of human diseases and cancers:

  • Hodgkin’s and Burkitt’s lymphoma
  • Nasopharyngal carcinoma
  • Main cause of post-transplant lymphoproliferative disease (PTLD) in immune suppressed transplant patients
  • Increases the risk of certain autoimmune diseases, e.g. lupus erythematosus, rheumatoid arthritis and multiple sclerosis
  • Plays a role in the development of chronic fatigue syndrome (CFS)

The latent EBV Antigens

During latent infection EBV expresses a small number of genes (e.g. EBNA1 -3 and LMP1 -2). Three major types of latency can be differentiated by their distinct expression patterns and are associated with the various types of diseases and cancer. Both, humoral and cellular (mainly CTL) immune responses play a role in controlling the primary and the latent phases of EBV infection.

JPT's Peptide Tools to Study EBV (Epstein-Barr Virus):

Cellular Immune Response Profiling

PepMix™ Peptide Pools for antigen specific stimulation of T-cells in

  • Immune monitoring of high-risk patients
  • Qualification of immunodominant antigens
  • Validating clinical T-cell assays

PepMix™ Collection EBV
The PepMix™ Collection EBV provides peptide pools (2 aliquots each) of 13 immunodominant antigens in one plate for fast and economic immune response profiling.

EBV PepMix™ Peptide Pools

Individual peptide pools comprise overlapping peptide scans through single immunodominant antigens:

Tailored EBV PepMix™ Peptide Pools
Peptide Pools tailored for your specific needs!

> PepMix™ Peptide Pools Product Page

PepTrack™ Peptide Libraries for T-cell assays in

  • High-throughput T-cell epitope discovery
  • Monitoring of cellular immune response
  • Clinical trials

> PepTrack™ Peptide Libraries Product Page

Custom Peptide Synthesis

We are the experts for peptide synthesis with highest quality optimized for many applications. Our peptide synthesis service has a very high success rate (over 99%) as we optimize the appropriate peptide synthesis method for each peptide.
If you would like to order a quality peptide synthesis using regulated processes, choose JPT!

> Custom Peptide Synthesis Product Page

Humoral Immune Response Profiling

Peptide Microarrays for humoral immune response profiling in

  • Immune monitoring of humoral responses
  • Profiling of EBV specific samples or antibodies
  • Evaluation of co-infection
  • Detection of epitopes and epitope spreading

Catalog RepliTope™ Peptide Microarrays
Ready-made peptide microarrays displaying overlapping peptides through single immunodominant antigens: BARF1, BMLF1, BMRF1, BRLF1, BZLF1, EBNA-LP, EBNA1, EBNA2, EBNA3a, EBNA3b, EBNA3c, LMP1, LMP2, GP350/340.
Catalog RepliTope™ Antigen Collection
The RepliTope™ Antigen Collection combines overlapping peptides for all the proteins above on one microarray for optimal coverage of the most important antigens in a single experiment.
> RepliTope™ Peptide Microarrays Product Page

Tailored PepStar™ Peptide Microarrays
You define content and layout, we provide economic and fast production in our regulated clean-room environment. We also offer our assay and analysis service using your samples with your tailored peptide microarray.
> PepStar™ Peptide Microarrays Product Page

Peptide ELISA

Our tailored Peptide ELISA plates are offered as stand alone service for mapping of epitopes and definition of protein interaction sites or as validation assay to confirm results obtained with JPT’s peptide microarrays.

> Peptide  ELISA Product Page

Clinical Peptides

Clinical Peptides

JPT’s Clinical Peptides product lines Clinical Grade and ISO Plus are produced in production environments that are regulated by an enhanced ISO 9001:2015 quality management system for the stringent product requirements of immunotherapy as well as vaccine and drug development. Depending on the specifics of the immunotherapy concept to be applied, the resulting products have been shown to be applicable in clinical applications.

> Clinical Peptides Product Page

Selected EBV Related References

"Evaluation of EBV- and HCMV-Specific T Cell Responses in Systemic Lupus Erythematosus (SLE) Patients Using a Normalized Enzyme-Linked Immunospot (ELISPOT) Assay"
Cassaniti et al, Journal of Immunology Research (2019)
"Measurement of CD8.sup.+ and CD4.sup.+ T Cell Frequencies Specific for EBV LMP1 and LMP2a Using mRNA-Transfected DCs"
Dae-Hee Sohn et al, PLoS ONE (2019)
"T-Cell Responses Targeting HIV Nef Uniquely Correlate With Infected Cell Frequencies After Long-Term Antiretroviral Therapy"
Thomas et al, PLoS Pathogens (2019)
"PRAME Peptide‐Specific CD8+ T Cells Represent the Predominant Response Against Leukemia‐Associated Antigens (LAAs) in Healthy Individuals"
Matko et al, European Journal of Immunology (2018)
"Dynamics of Virus‐Specific T Cell Immunity in Pediatric Liver Transplant Recipients"
Arasaratnam et al, American Journal of Transplantation (2018)
"Epstein-Barr Virus (EBV)-derived BARF1 Encodes CD4-and CD8-restricted Epitopes as Targets for T-cell Immunotherapy"
Kalra et al, Cytotherapy (2018)

More references

Selected EBV Related Testimonials

"My group is developing therapeutic strategies for using in vitro expanded virus-specific T cells (VSTs) for the treatment of viral infections in immunocompromised patients. We recently demonstrated the feasibility and clinical benefit associated with the infusion of rapidly generated single-culture VSTs, manufactured using JPT's GxP PepMix™ peptide pools covering 12 immunogenic antigens from five viruses (EBV, AdV, CMV, BK, and HHV6). When administered to 11 allogeneic stem cell transplant recipients, 8 of whom had up to four active infections, these VSTs produced an overall 94% response rate."
Ann Leen, PhD, Baylor College of Medicine, Houston, TX, USA  

"The main focus of my research group at the Charité in Berlin is the development of novel immunotherapeutic approaches against cancer and infectious diseases. For reliable monitoring of tumor and virus specific T-cell responses we have a permanent need for peptides and peptide pools that are produced in a regulated environment for application in a clinical environment. JPT has been a long term and dedicated partner in this regard which continuously works on improving it's peptide based services."
Prof. Dr. Carmen Scheibenbogen, Charité Berlin, Germany

More testimonials

Check our list of products,
click and go.

Quality Assurance

All production is performed according to ISO 9001:2015 standards

Stay in touch and be the first to receive the latest news!